Vorinostat (suberoylanilide hydroxamic acid, SAHA) provides prolonged safety and clinical benefit to patients with advanced cutaneous T-cell lymphoma (CTCL)

被引：0

作者：

Duvic, Madeleine ^{[1
]}

Olsen, Elise A. ^{[2
]}

Breneman, Debra ^{[3
]}

Pacheco, Theresa R. ^{[4
]}

Parker, Sardeta ^{[5
]}

Vonderheid, Eric C. ^{[6
]}

Ricker, Justin L. ^{[7
]}

Rizvi, Syed ^{[7
]}

Chen, Cong ^{[7
]}

Boileau, Kathleen ^{[7
]}

Cooley, Paulette ^{[7
]}

Geskin, Larisa J. ^{[8
]}

机构：

[1] MD Anderson Canc Ctr, Houston, TX USA

[2] Duke Univ, Durham, NC 27706 USA

[3] Univ Cincinnati, Med Ctr, Cincinnati, OH 45221 USA

[4] Univ Colorado, Hlth Sci Ctr, Aurora, CO USA

[5] Emory Univ, Atlanta, GA 30322 USA

[6] Johns Hopkins Univ, Baltimore, MD 21218 USA

[7] Merck Res Labs, Upper Gwynedd, PA USA

[8] Univ Pittsburgh, Pittsburgh, PA 15260 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2582

引用

页码：761A / 761A

页数：1